92 results about "Neuroregulation" patented technology

A method and system for neuromodulating vagus nerve(s) to provide therapy for neurological and neuropsychiatric disorders comprises implantable and external components. The pulsed electrical stimulation to vagus nerve(s) is used for disorders such as epilepsy, depression, anxiety disorders, neurogenic pain, compulsive eating disorders, obesity, dementia including Alzheimer's disease, and migraines. The pulsed electrical stimulation to vagus nerve(s) may be provided using one of the following stimulation systems, such as: a) an implanted stimulus-receiver with an external stimulator; b) an implanted stimulus-receiver comprising a high value capacitor for storing charge, used in conjunction with an external stimulator; c) a programmer-less implantable pulse generator (IPG) which is operable with a magnet; d) a programmable implantable pulse generator; e) a combination implantable device comprising both a stimulus-receiver and a programmable IPG; and f) an IPG comprising a rechargeable battery. In one embodiment, the external components such as the programmer or external stimulator may comprise a telemetry means for networking. The telemetry means therefore allows for interrogation or programming of implanted device, from a remote location over a wide area network.

A method and system for providing electrical pulses for neuromodulating a cranial nerve of a patient utilizing an implantable stimulator. The implantable stimulator comprising a pulse generator module and a stimulus receiver module for coupling with an external stimulator. Control circuitry ensures selective operation of one pulse generator module. The external stimulator comprises a telemetry module for remotely activating (or de-activating) programs over the internet, to arrive at the optimal program for each patient. Once the optimal “dose” is titrated using the external stimulator, the implanted pulse generator can then be programmed to such parameters. The external stimulator in conjunction with the implanted stimulus receiver can override the implanted pulse generator, to provide extra dose of therapy or to conserve the implanted battery. The external stimulator is also networked to other computers. The external programmer may also comprise a global positioning system (GPS) module for determining patient location.

A neuromodulation therapy system includes a programmer and a stimulation system. The stimulation system is capable of storing multiple data sets, each data set effecting an independent therapy. The stimulation system includes a display mechanism that can display certain imagery to distinguish visually one therapy from another therapy.

Methods for allowing a user to control a neuromodulator to modify a cognitive state being experienced by the user. The user may select a waveform ensemble from a hand-held user device having an interface, and the user may adjust the perceived intensity of the applied waveform ensemble with the user device while the waveform ensemble is being applied. Also described are methods of managing communication between the hand-held user device (such as a smartphone or the like) and a wearable neurostimulator. Methods of displaying and visually tracking and controlling the applied waveform ensemble are also described herein.

The present invention relates to new compounds which are Heterocyclic derivatives of formula (I) wherein A, B, P, X, Y, Q, W, R1 and R2 are defined in the description. Invention compounds are useful for treating central or peripheral nervous system disorders and other disorders which are affected by the neuromodulatory effect of mGluR5 positive allosteric modulators such as cognitive decline and also to treat both positive and negative symptoms in schizophrenia.

Disclosed are methods and systems for treatment planning for deep brain or superficial neuromodulation using ultrasound and other treatment modalities impacting one or multiple points in a neural circuit to produce acute effects or Long-Term Potentiation (LTP) or Long-Term Depression (LTD) to treat indications such as neurologic and psychiatric conditions. Ultrasound transducers or other energy sources are positioned and the anticipated effects on up-regulation and / or down-regulation of their direction of energy emission, intensity, frequency, firing / timing pattern, and phase / intensity relationships mapped onto the recommended treatment-planning targets. The maps of treatment-planning targets onto which the mapping occurs can be atlas (e.g., Tailarach Atlas) based or image (e.g., fMRI or PET) based. Atlas and imaged-based maps may be representative and applied directly or scaled for the patient or may be specific to the patient.

The present invention provides a single surgical method, procedure and / or system that creates open visual and physical access to an identified spinal treatment site that initially comprises spinal levels to be treated, wherein the spinal levels comprise at least one dorsal root ganglion. A spinal treatment procedure is performed generally in combination with implantation of a neuromodulation system that may comprise placement of electrical lead(s) on the at least one dorsal root ganglion, wherein each lead is in operative connection with a pulse generator that may also be implanted during the surgical method. Electrical stimulation may be generated with the pulse generator through the electrical leads to the at least one dorsal root ganglion during and / or after the closure of the identified spinal treatment site.

The invention expands indications of a neuregulin in cardiovascular diseases, including sinus tachycardia and chronic atrial fibrillation. When the neuregulin is given to a mammal, the electrocardiogram PR interval thereof is found to be prolonged, and the heart rate is slowed down. The effect of slowing down the heart rate of the neuregulin can be used for anti-arrhythmias, and the chronic effect on the vagus nerve activity thereof can be used for treating sinus tachycardia and chronic atrial fibrillation.

Disclosed herein are portable and integrated modules and devices for non-intrusive neuromodulation and monitoring of heart function, and methods of operation thereof. The modules and devices include a monitoring unit, an electrical stimulation inducing unit, and three electrodes, such that one of the electrodes is dual-function, being controllably utilized for neuromodulation or for monitoring of heart function.

A method of energetic medicine wherein a practitioner corrects faults in various functional categories of the system that controls vegetative functions in the body of the subject. The method is comprised of the steps of applying specific clinical algorithms consisting of queries and corrective statements to assess and then train this system toward optimal function. The medium by which this is achieved is verbal and / or other than conscious communications from the practitioner to subject, as well as application of physical stimuli. Communication from subject to the practitioner is determined by monitoring an indicator of autonomic function.

It is intended to provide a safe composition for preventing or treating obesity or related complications which has an autonomic nervous control effect, in particular, an effect of enhancing sympathetic nervous activity and an effect of promoting energy metabolism. Thus, a medicinal composition, a food or a drink containing 2,3-dihydro-3,5-dihydroxy-6-methyl-4H-pyran-4-one and having an autonomic nervous control effect and an effect of promoting energy metabolism is provided.

Disclosed are the use of neuregulin proteins in preparing a medicine for preventing, treating or delaying preserved ejection fraction cardiac failure in mammals, and a method for using the medicine. Also provided in the present invention is a method for preventing, treating or delaying preserved ejection fraction cardiac failure in mammals, comprising using the medication containing the neuregulin proteins in a special population having the disease or being at risk of having the disease.

The present disclosure provides a method and system for treating affective disorders such as depression and / or anxiety and / or related disorders through neuromodulatory intervention that includes brain targets within the orbitofrontal cortex (OFC). This method includes the application of electrical stimulation through an electrical signal generator device where the distal end of the device comprises at least one stimulating electrode in contact with the OFC. The treatment system includes patient selection, implantation of at least one stimulating electrode in contact with the OFC, acute or chronic electrical stimulation of the OFC, and evaluation of the effects of stimulation on clinical symptoms and status.

The invention discloses application of galanthamine in prevention and treatment for soybean meal-induced enteritis of fishes. According to a neuroregulation theory of intestinal mucosal immunity, in combination with two methods of disease modeling and biological information analysis, it is inferred that the galanthamine is a potential medicine for preventing and treating the soybean meal-induced enteritis; it is proved by an experiment that the galanthamine can activate expression of anti-inflammatory cytokines in intestinal tracts of bred fishes through addition into feed or intramuscular injection in backs, inhibit intestinal inflammations, maintain tight junctions of intestinal epithelium barriers, and inhibit intestinal epithelium apoptosis, therefore the enteritis caused by a soybeanmeal feed is relieved, recovery of growth of the fishes can be achieved, and therefore the galanthamine can be taken as a novel feed additive with an anti-inflammatory effect or an injection with an anti-inflammatory effect for injection operation.

The invention relates to a method for stimulating nerves and adjusting hormone secretion. The method comprises the following steps of: providing and assembling a set of stereo equipment, an electronic vibration device and a seating and lying device arranged on the vibration device; playing rhythmed music by utilizing the stereo equipment to generate a music sound wave rhythmed vibration propagation effect; and driving and controlling the vibration device to drive the seating and lying device to generate rhythmed vibration by utilizing a music rhythm frequency stage power signal, playing a rhythm dynamic image correspondingly matched with the music rhythm by utilizing an image video playing device, feeling dynamic rhythm through audition and somatesthesia, feeling rhythmed vibration through vision and forming multiple rhythmed vibration and dynamic change signals while stimulating the nerve system to be excited and impulsive to release neurotransmitter and adjust, dominate and maintain steady-state hormone secretion. The method is simple and convenient to use, takes an effect on people enjoying in music art, and is suitable for caring the physical and mental health of people at home and in healthcare places.

Disclosed are devices, systems and methods for non-invasive neuromodulation system for treating inherited or acquired retinal, choroidal and optic nerve disorders caused by acute or chronic dysregulated reduced ocular blood flow (OBF) and / or energy failure by up regulation of trigemino-vascular system (TVS), trigeminal autonomic brain reflexes (TABRs) and pancreatic trigemino-vagal reflex (TVR) through stimulation of ophthalmic nerve (V1), more specifically but not limited to SP, and CGRP containing unmyelinated C nerve fibers. The invention, in some embodiments thereof, relates to the methods for enhancing SP and CGRP expression in neurovascular tissue of the retina and choroid. The invention, in some embodiments thereof, relates to SP / CGRP mediated pathways, including those involved in vasodilatation, augmentation of OBF, RPE proliferation, prevention of apoptosis, suppressing neuroinflammation, promoting migration and differentiation of vascular endothelial cells as well as mobilization of endogenous mesenchymal stem cells (EMSCs) from the bone marrow to the circulation to accelerate tissue repair. The site of stimulation of V1 nerve includes but not limited to; nasal vestibule nasal bridge, forehead, and upper eyelids. Additionally or alternatively, the subject's sympathetic nervous system (SNS) is down regulated by sympatholytic agents specifically antioxidants. The subject's TVS and autonomic nervous system (ANS) are modulated in a manner that is effective to treat the subject for retinal, choroidal and / or optic nerve disorders. In some embodiments, the devices are handheld, portable with nose supported, having one or more intra-nasal or extra-nasal application heads. The signal can include vibration, chemical, ultrasonic, optical, electrical, hybrid electro-optical or combination of two or more of these types of stimuli. The invention, in some embodiments thereof, relates to a method for decreasing vascular resistance, enhancing vasodilatation in ophthalmic artery and its branches by the release of Vasoactive intestinal peptide (VIP),substance P and CGRP thereof increasing OBF to the retina, choroid and optic nerve in subject's with acute or chronic dysregulated, reduced OBF. The invention, in some embodiments thereof, is also related to the methods for improving delivery of oxygen, glucose, vitamin A, humoral mediators, growth factors, stem cells and pharmacological agents to the targeted tissues of the retina, choroid and optic nerve. The invention, in some embodiments thereof, relates to the methods for improving pancreatic insulin secretion, thereof to enhance glucose uptake by PRs and other retinal cells. Additionally or alternatively, the invention relates to restoration of transduction of signaling in cone PRs by ONS induced glutamate release. The methods of the invention, in some embodiments thereof, include priming of the retina choroid and optic nerve thereof to enhance the efficacy of cell transplantation therapy. The methods of the invention, in some embodiments thereof, also include identifying a subject prone to or suffering from a disease or condition associated with reduced OBF. Methods of the invention, in some embodiments thereof, may also include monitoring the subject for prophylactic treatment where the patients are at pre-clinical stage of the disease. The OBF of subjects who had received neuromodulation treatment may also be monitored for re-treatment.The present invention, in some embodiments thereof, relates to a method and / or device for treatment of dysregulated reduced blood (e.g. reduced ocular blood flow) and, more particularly, but not exclusively, to methods and / or devices for treatment retinal, choroidal and optic nerve disorders. Optionally, treatment may include application of an effective amount of ONS ophthalmic nerve stimulation alone and / or in combination with pen-ocular administration of substance Neuropeptides / Platelet Rich Plasma (N / PRP) and / or ascorbic acid as a sympatholytic agent

The invention discloses a natural galenical for treating gynecologic diseases, which comprises the following raw materials in parts by weight: 1-3 parts of motherwort, 1-5 parts of dandelion, 1-2 parts of plantain, 2-4 parts of willow and 1-3 parts of white tea. The preparation method of the natural galenical comprises the following steps: extracting the motherwort, the dandelion, the plantain, the willow and the white tea and mixing according to a certain proportion so as to prepare the natural galenical. All the medicaments of the invention are completely extracted by adopting purely natural plants, can effectively act on the organism nerve of a person, regulate the endocrine system in the organism, can secrete mucus to protect the mucous membrane of the cavity tract, enhance the immunity of the organism, resist bacteria and diminish inflammation, thereby acting as a rehabilitation function. By clinical experiments, the total treatment effect of the invention is obviously enhanced in comparison with the traditional medicine, and pelvic inflammation can be radically cured.

The invention relates to an application of neuregulin 1 (NRG1) and acceptor thereof as a target for preparing and screening anti-epileptic drugs. The application of NRG1 for inhibiting the development and progression of epilepsy by activating leukemia virus oncogene homolog 4 (ErbB4) of bird red blood cells in inhibitory neurons in the brain is proposed for the first time; and novel target is provided for effective prevention, control or treatment of the epilepsy.

The invention discloses an external-use product in Yao-nationality medicine for going through the veins, strengthening muscles and bones, passing meridian, promoting blood circulation, improving symptom of hand-foot cooling and for foot bath. The product is mainly prepared from natural and unique valuable and rare medicinal materials such as caulis spatholobi, Chinese starjasmine stem, rhizome drynariae, roots and stems of Kadsura heteroclita, rhizome zingiberis, beautiful sweetgum fruit, cinnamomum camphora, fructus evodiae and cassia twig by the ancient prescription of Yao nationality, and is an external-use product for foot bath of consumers. The product has favorable functions of going through the veins, strengthening muscles and bones, passing meridian, dispelling cold, protecting the skin, promoting blood circulation, improving cooling of hands and feet, balancing yin and yang, adjusting internal secretion, improving body fluid circulation, allaying tiredness, enhancing the nervous regulation ability, alleviating arthralgia of muscles, enhancing the immune function, improving the immunity, delighting mood, alleviating mental stress and easing sleep. The product is particularly suitable for sub-health crowds cool in hands and feet, unsmooth in qi and blood, in morning stiffness, unsmooth in meridian and cool in hands and feet.

Provided is an effective stereognosis training system that integrates hardware and software to provide a simple, reliable, quantitative system to provide tactile rehabilitation and progress monitoring. The system can include an interactive device including a novel set of objects, that are combined with neuromodulatory systems such as wireless closed-loop vagus nerve stimulation to improve neural plasticity and expedite functional recovery. The system can send updates to therapists or clinicians to monitor progress and encourage compliance with prescribed therapy.

The invention provides compound of brain protein hydrolyzate and maleic acid and a method for preparing the same and also provides a method for preparing dispersible tablets of the medicinal compound of brain protein hydrolyzate and maleic acid, belonging to the technical field of the medicament. The medicinal compound of brain protein hydrolyzate and maleic acid is the peptidergic neural nutritional medicament specially used for the brain and can act on the central nervous system in various ways to adjust and improve the neuronal differentiation. The medicinal compound of brain protein hydrolyzate and maleic acid can promote the synthesis of the brain protein through a blood-brain barrier, has the efficacy of preventing hypoxia, improving the brain energy metabolism and providing neurotransmitter, peptide hormones and coenzyme precursors and can be used for preparing the medicament for improving insomnia, headache, memory loss, irritability and other symptoms, promoting the rehabilitation of acute cerebral infarction and acute brain injury and treating brain dysfunction.

The invention discloses a bee venom rheumatism ointment and a preparation method and use thereof, and relates to the field of Chinese herbal medicine. The ointment is made by taking bee venom as a monarch drug, selecting 15-20 parts of rhizoma chuanxiong, 15-20 parts of radix saposhnikoviae, 10-15 parts of myrrh, 15-20 parts of radix angelicae, 10-15 parts of radix scrophulariae, 10-15 parts of radix angelicae pubescentis, 10-15 parts of flos carthami, 2 parts of menthol, 3 parts of camphor and 1 part of borneol to serve as raw materials to be decocted, and adding 0.2 gram of dry bee venom into every 100 grams of the ointment. The ointment can be prepared through decoction with water or decoction with oil, the added dry bee venom and the components of the ointment can assist in the absorption of the bee venom, and the anaphylactic reaction of the human body to the bee venom is eliminated; the functions of inflammatory resistance and neuroregulation of the bee venom can enhance the effects of relieving pain and inflammation of the ointment; the ointment has the effects of antiphlogosis, relieving pain, promoting blood circulation to remove blood stasis, and dispelling wind and eliminating dampness.

Featured are intravaginal devices and electrical stimulation devices, systems, thereof, and methods of using the devices and systems thereof to observe pelvic floor movements in order to diagnose, treat, or prevent urinary and fecal incontinence disorders (e.g., urge incontinence) and their accompanying symptoms or to diagnose and / or improve the efficacy of neuromodulation therapy.

Methods of use, formulations, and devices for delivering therapeutic drugs locally to the region of the spleen are described herein. A method for treating sepsis and other inflammatory disease conditions can include inserting a drug delivery system inside the body, advancing the device to the spleen through the splenic artery, splenic vein or other blood vessel adjacent to the splenic nerves, or within a ligament associated with the spleen, such as the splenorenal or gastrosplenic ligaments.

The present invention relates to a neuromodulation apparatus and methods of using the neuromodulation apparatus for treating bladder dysfunction.

Systems and methods for neuromodulation therapy are disclosed herein. A method in accordance with embodiments of the present technology can include, for example, intravascularly positioning a plurality of ablation electrodes within a blood vessel lumen at a treatment site. The method can include analyzing a renal neuromodulation target site of a patient to obtain patient-specific data related to the renal neuromodulation target site, and based on the patient specific data, delivering neuromodulation treatment to the patient via one or more of the ablation electrodes.

Electrical stimulation of specific facial and lingual nerves creates a more sustained pulsatility activity compared to stimulation of other cranial nerves. Pulsatility of arteries has intrinsic time constraints related to the time for vasodilation / constriction and time to return to baseline (TBL) after electrical stimulation which may affect the pulsatility response. Control of temporal patterning and the stimulation waveform maximizes the physiological response to cerebral pulsatility and its resulting effects on cerebral spinal fluid penetration into the brain parenchyma for a multitude of therapeutic uses including clearing misfolded proteins and / or administered pharmacological agents, diluting endogenous neurochemical concentrations within the brain, and reducing non-synaptic coupling.